Lai Wang Sells 1,169 Shares of BeOne Medicines (NASDAQ:ONC) Stock

Posted by George Bondi on Jun 20th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) insider Lai Wang sold 1,169 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $265.39, for a total value of $310,240.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lai Wang also recently made the following trade(s):

On Thursday, June 11th, Lai Wang sold 756 shares of BeOne Medicines stock. The shares were sold at an average price of $261.00, for a total value of $197,316.00.
On Monday, June 8th, Lai Wang sold 1,367 shares of BeOne Medicines stock. The stock was sold at an average price of $269.38, for a total transaction of $368,242.46.

BeOne Medicines Stock Performance

ONC opened at $270.15 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $239.25 and a 12-month high of $385.22. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49. The firm has a 50 day moving average of $295.32 and a two-hundred day moving average of $312.15.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Truist Financial reaffirmed a “buy” rating and issued a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Barclays lifted their price objective on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Wolfe Research began coverage on BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $390.00.

Read Our Latest Research Report on BeOne Medicines

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fiera Capital Corp boosted its stake in shares of BeOne Medicines by 20.1% during the 3rd quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock worth $8,557,000 after acquiring an additional 4,205 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of BeOne Medicines by 100.6% in the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after purchasing an additional 97,244 shares in the last quarter. Slow Capital Inc. increased its stake in shares of BeOne Medicines by 51.5% in the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after purchasing an additional 9,280 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in BeOne Medicines in the 3rd quarter worth about $2,726,000. Finally, Capital International Sarl raised its holdings in BeOne Medicines by 2.7% in the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after purchasing an additional 3,956 shares during the period. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.